CD64 (FcγRI) receptors represent highly potent trigger molecules for activated
polymorphonuclear cells (PMN) and mediate lysis of a range of tumors in the presence of …

CD20 Abs induce clinical responses in lymphoma patients, but there are considerable
differences between individual patients. In 51 Cr release assays with whole blood as effector …

CD19 is a pan B-cell surface receptor expressed from pro–B-cell development until its down-
regulation during terminal differentiation into plasma cells. CD19 represents an attractive …

Abstract Human CD32B (FcγRIIB), the low-affinity inhibitory receptor for IgG, is the
predominant Fc receptor (FcR) present on B cells. Immunohistochemical and expression …

CD20 is highly expressed on normal and malignant B cells, and is a well-established target
of antibody therapeutics for B cell leukemias and lymphomas. However, a limitation of …

Bispecific murine monoclonal antibodies that target tumor and FcγRIII (CD16) can promote
relevant tumor lysis by large granular lymphocytes. For these antibodies to be clinically …

Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action
by engaging the immune system. Unfortunately, cures rarely occur and patients display …

Bispecific antibodies (bsab) offer a promising approach for optimizing antibody-based
therapies. In the present study,[(CD20) 2 xCD16], a recombinant CD20-and CD16-directed …

Promising results from clinical trials with unconjugated antibodies stimulated renewed
interest in immune effector mechanisms of monoclonal antibodies (MoAbs). We investigated …

Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …